About EverLife Capital
EverLife teaches investors and financial professionals how to evaluate longevity biotech companies using a repeatable 25-criteria process. No biology background required.
I am Eric Pemper. My background is in computer engineering and more than 25 years of building businesses and teams. My early longevity investments taught me that an exciting pitch is not enough. I wanted a more disciplined way to compare scientific evidence, financing needs and development timelines.
The 25-Gate Framework asks two connected questions: could the technology add meaningful lifespan or healthspan value, and do the company economics justify deeper research? EverLife teaches you to examine the evidence and financial assumptions, identify unanswered questions, and form your own research conclusion.
Why Learn This Process
A company pitch can mix convincing science with unanswered investment questions. Learning a consistent process helps you separate the treatment idea, evidence of patient benefit, business ownership and financing assumptions.
Longevity biotech looks similar:
Understand what the technology could accomplish and distinguish laboratory findings from controlled human evidence.
Test the business case, including valuation, cash runway, future financing and dilution, before deciding what deserves deeper independent research.
A useful evaluation ends with more than a score. You should be able to explain what has been demonstrated, which assumptions remain untested, how much financing the company may need, and the next result that could change your view. You should also know when a scientific, clinical or financial specialist is needed.
What A Useful Evaluation Looks Like
Who I Am
I'm Eric Pemper, founder of CuraDebt and independent longevity biotech publisher.
I am not a doctor, scientist, registered investment adviser, or fiduciary. I am an operator and research publisher who studies the intersection of business, science, capital allocation, and healthspan potential.
My background includes:
B.S. in computer engineering from the University of California in San Diego
25+ years building and leading companies
Creating repeatable frameworks for evaluating hard problems
Applying that discipline to study longevity biotech
How EverLife Evaluates Companies
EverLife Capital uses a structured 25‑Gate Framework to evaluate longevity biotech companies across:
Scientific rationale & mechanism quality
Clinical development path
Leadership and capital discipline
Regulatory timeline
Commercial potential
Financial risk
The framework is a research aid. Scores are reasoned assessments of incomplete information, not probabilities of success or investment recommendations. Original Scout and Tracker admissions remain in the dated record when evidence changes or a company fails. Current assessments are updated separately.
Learn Through Company Cases
The free weekly lesson teaches a useful evaluation concept. The course develops the complete process through:
Worked company evaluations
Plain-English explanations of the technology
Practical questions and evaluation exercises
25-Gate assessments with evidence and financial assumptions
Milestone checklists and dated follow-up
Commentary on areas such as inflammation, cellular reprogramming, senescence, cardiovascular biology, and other healthspan‑related fields
When I have a financial interest in a company discussed, I disclose it clearly. I currently hold positions in Yuva Biosciences and Repair Biotechnologies.
What This Is Not
EverLife Capital is not:
Investment advice
Medical advice
A managed investment fund
Personalized financial planning
I do not know your financial situation, risk tolerance, time horizon, or medical circumstances. Nothing published here is tailored to you or should be construed as a recommendation to buy, sell, or hold any security. Consult qualified professionals for financial, legal, and medical decisions.
Important Disclosures
EverLife Capital is an independent research publication intended for general educational purposes only. It is not registered with the SEC as an investment adviser. Content should be viewed as impersonal commentary and research, not individualized advice.
FAQ
Is EverLife Capital investment advice?
No. EverLife Capital is educational research and impersonal commentary only. It is not investment, legal, tax, medical, or personalized financial advice. Nothing published here is a recommendation to buy, sell, hold, allocate to, or avoid any security, company, fund, or private investment.
Are you a registered investment adviser?
No. I am not a registered investment adviser, broker-dealer, physician, scientist, fiduciary, or fund manager. I publish independent educational research based on my own study of longevity biotech companies, mechanisms, clinical developments, and market activity.
What does EverLife Capital publish?
The free weekly lesson introduces an evaluation concept through a real technology or company. The course teaches a structured process and uses worked company cases to practice interpreting evidence, financing and valuation. Case topics include:
Mechanisms of aging
The top causes of death and major age-related diseases
Earlier-stage breakthrough science that could matter if the biology translates
When something important happens in the industry - such as a major acquisition, partnership, clinical readout, regulatory development, or “smart money” move by pharma or institutional investors - I may publish an additional note.
What is the research tracker?
The research tracker is a hypothetical, paper-only tool I use to test my 25-Gate Framework over time. It is not a real-money portfolio, not a fund, not a managed account, and not a product offered to subscribers. When a company is added to the tracker, it means the framework flagged it as worth continued observation. It does not mean I am recommending the company or that I believe anyone should buy it.
What is the watchlist?
The watchlist is for companies, mechanisms, or scientific areas that are interesting but not yet strong enough for the research tracker. A company may be placed on the watchlist because the science is promising but early, the clinical data is incomplete, the capital structure is unclear, the company overlaps too closely with another tracked company, or the risk/reward picture is not yet developed enough.
How do you decide which company is the “best pick” for a deep dive?
Each deep dive uses my 25-Gate Framework to compare companies across science, clinical evidence, leadership, capital discipline, competitive positioning, commercial potential, and risk.
Sometimes the “best pick” is not the highest-quality company in isolation. It may be the company that adds the most differentiated exposure to a mechanism, avoids duplicating an existing tracker company, or offers the clearest way to study a biological theme.
The framework does not pick stocks. It helps me decide what is worth studying more closely.
Do you personally invest in companies you write about?
Sometimes. When I have a financial interest in a company discussed, I disclose it clearly. I currently hold personal equity in Repair Biotechnologies and Yuva Biosciences. My personal holdings are not recommendations. They may be illiquid, high-risk, private, early-stage, or unsuitable for other people. Readers should not rely on my personal activity as guidance for their own decisions.
Who is EverLife Capital for?
EverLife is designed for self-directed investors, wealth professionals, family-office and investment analysts, and business owners who want to evaluate biotechnology without needing a biology background. It helps readers ask better questions and identify when specialist review is needed. It does not tell readers what to buy.
The goal is to help readers understand what may matter in the future of healthy aging, not to tell anyone what to buy.
How can I contact the publisher?
Please email: [email protected].
About EverLife Capital
Supporting longevity biotech starts with understanding it. EverLife helps you learn how treatments work and what to ask before backing a company. No biology degree required.
Get the Free Weekly NewsletterI am Eric Pemper. I have spent more than 25 years building businesses, including CuraDebt, because I wanted my work to make a positive difference. Longevity biotech showed me another way to support potentially life-changing work. My early investments taught me that a compelling mission and exciting biology are not enough. Before backing a company, I want to understand what a treatment could do, what evidence exists, and whether the company's economics justify the risk.
EverLife's free weekly newsletter explains how treatments are supposed to work and walks through real company cases, so you can practice asking better questions and build your own judgment. If you want to go deeper, the course teaches the full 25-Gate Framework through lessons, exercises and worked assessments.
Scores are assessments of incomplete information, not probabilities of success. Original Scout and Tracker admissions remain in the dated research record when evidence changes, including adverse outcomes. A classification is not a holding or investment-performance result.
EverLife provides general education, not personalized investment or medical advice, trade alerts, a managed portfolio or accredited continuing-education credit. I am not a registered investment adviser, broker-dealer, physician or scientist. My disclosed personal holdings include Repair Biotechnologies and Yuva Biosciences. They are not recommendations.
Before EverLife, I founded CuraDebt.
Explore The Course